Method Developed to Identify Anti-Tumor Drugs to Increase Cancer Compounds Production
By Biotechdaily staff writers
Posted on 27 Aug 2007
Scientists have discovered a unique and patentable computer-assisted method to identify cancer compounds that could be used as anti-tumor agents for cancer patients. This technique allowed scientists to virtually screen databases, consisting of 15 million small molecules, without any biologic input, to identify eight compounds with anti-tumor potential. Posted on 27 Aug 2007
Although in the early stage, one of these compounds or more could serve as a lead cancer compound in Samaritan Pharmaceuticals, Inc.'s (Las Vegas, NV, USA) pipeline, after extensive preclinical efficacy and safety studies. Samaritan has exclusively licensed a patent application entitled "Structure-Based Drug Design of Steroid Inhibitors,” from Georgetown University (Washington DC, USA).
Samaritan Pharmaceuticals is a life-science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after phase II (proof of concept) human studies.
Related Links:
Samaritan Pharmaceuticals
Georgetown University
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
